International
The Morning Science

What science found today

‹
 

Research

RIPK1 inhibition limits expansion of pathogenic double-negative T cells in preclinical autoimmune lymphoproliferative syndrome models

Science · By Jingjing Li, Yayun Du, Jiaying Qiu, Xiaoliang Yu, Zhanhui Li, Haikuo Ma, Wei Zhang, Xiangping Xu, Qiuye Li, Cong Zhao, Dongmei Cao, Rui Li, Zhizhuo Du, Hu Liu, Xiaohu Zhang, Junjie Fan, Shaoyan Hu & Sudan He ·

The Brief

  • A preclinical study reports that RIPK1 inhibition limits the expansion of pathogenic double-negative T cells in autoimmune lymphoproliferative syndrome models.
  • The work was published in Science Translational Medicine, Volume 18, Issue 876, in November 2026.

Why it matters

It identifies RIPK1 inhibition as a possible way to restrain disease-driving T cells in autoimmune lymphoproliferative syndrome, though the evidence is preclinical.

Who’s affected

  • immunologists
  • researchers studying autoimmune lymphoproliferative syndrome

Science Translational Medicine, Volume 18, Issue 876 , November 2026.

Timeline

  1. Study published in Science Translational Medicine

  2. science.org

    RIPK1 inhibition limits expansion of pathogenic double-negative T cells in preclinical autoimmune lymphoproliferative syndrome models

How do you feel about this?

0 Comments

    RIPK1 inhibition limits expansion of pathogenic double-negative T cells in preclinical autoimmune lymphoproliferative syndrome models – The Morning Science